Beta amyloid grabs most of the headlines and research dollars for Alzheimer’s disease, but efforts to develop drugs targeting that brain protein have largely come up short. Pinteon Therapeutics is trying for a better outcome with drugs that block tau, a different protein that, despite also being associated with Alzheimer’s, has garnered much less attention.
Pinteon has spent the past two years quietly developing a tau-targeting drug. On Thursday, the Cambridge, MA-based company announced a $17 million investment and a plan to advance its lead compound through early-stage tests in humans. Morningside Ventures provided the financing for the Series A funding… Read more »
UNDERWRITERS AND PARTNERS
